32
Participants
Start Date
June 23, 2023
Primary Completion Date
October 1, 2026
Study Completion Date
October 1, 2026
CIS-DPI
"* Administration of cisplatin by inhalation (pulmonary route) using single-use RS01 capsule-based device and CIS-DPI hard capsules containing 2.5 mg, 5 mg, and 10 mg cisplatin.~* CIS-DPI, administered once-a-day, 5-days on followed by 2-days off. Daily dose to be administered will range from an initial dose of 2.5 mg cisplatin to a maximal theoretical dose of 30 mg (i.e., dose 1 to dose 7)."
RECRUITING
Institut Jules Bordet - Hôpital Universitaire de Bruxelles, Brussels
RECRUITING
GHDC, Charleroi
RECRUITING
CHU Helora - Site Jolimont, Jolimont
RECRUITING
AZ Groeninge, Kortrijk
RECRUITING
CHU Sart Tilman, Liège
RECRUITING
CHU Ambroise Paré, Mons
RECRUITING
AZ Delta, Roeselare
NOT_YET_RECRUITING
Université Paris-Saclay, UVSQ, APHP - Hôpital Ambroise Paré, Boulogne-Billancourt
NOT_YET_RECRUITING
Centre François Baclesse de Caen, Caen
NOT_YET_RECRUITING
Hôpital Européen Georges Pompidou, Paris-Cite University, Paris
NOT_YET_RECRUITING
L'Institut de Cancérologie de l'Ouest, Saint-Herblain
RECRUITING
Instituto Oncologico Dr Rosell, Hospital Universitario Dexeus, Barcelona
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Hospital Universitario La PAZ, IdiPAZ, Madrid
RECRUITING
Hospital Universitario Virgen del Rocío, Seville
Lead Sponsor
Inhatarget Therapeutics
INDUSTRY